The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.
Abstract
BACKGROUND: Hypertension is a complex trait with an ill-defined genetic predisposition, in which adrenergic mechanisms seem to be involved even at the early stages. Chromogranin A is a pro-hormone stored and released with catecholamines by exocytosis; its fragment catestatin, formed in vivo, inhibits further catecholamine release as an antagonist at the physiologic trigger for secretion, the neuronal nicotinic cholinergic receptor. METHODS: We measured catestatin by radioimmunoassay in n = 277 subjects stratified by blood pressure (n = 61 hypertensive, n = 216 normotensive), and if normotensive by genetic risk of developing hypertension: family history positive (n = 176) versus negative (n = 40). Maximum likelihood analysis tested for bimodality. Involvement of catestatin in pathophysiology was probed by measurements of catecholamines and leptin, and the hemodynamic responses to environmental (cold) stress. RESULTS: The normotensive offspring of patients with hypertension already had diminished catestatin (P = 0.024), and family history was a better predictor of catestatin than age, ethnicity or gender (P = 0.014). Greater catestatin variance among family history-positive individuals (P = 0.021) suggested heterogeneity in this group, and a bimodal distribution (P < 0.001) identified 4.3% of individuals in a lower mode of catestatin values, all with positive family histories (P = 0.05). Catestatin correlated inversely with body mass index (r = -0.215, r(2) = 0.046, n = 276, P < 0.001) and plasma leptin (r = -0.203, r(2) = 0.041, n = 212, P = 0.003), while body mass index and leptin correlated directly (r = 0.59, r(2) = 0.350, n = 212, P < 0.001). Family history-positive individuals had greater epinephrine excretion (P = 0.037) in addition to diminished catestatin, suggesting an inhibitory effect of catestatin on chromaffin cells in vivo. Low plasma catestatin predicted enhanced pressor response to a sympathoadrenal stressor (cold stress; r = -0.184, r(2) = 0.034, n = 211, P = 0.007), suggesting an adrenergic mechanism whereby diminished catestatin might predispose to later development of hypertension. In white subjects, diminished catestatin also predicted greater systemic vascular resistance responses to cold stress (r = -0.307, r(2) = 0.094, n = 75, P = 0.007), a relationship not found in Blacks (r = 0.122, r(2) = 0.015, n = 94, P = 0.243). CONCLUSIONS: We conclude that catestatin is diminished early in the course of development of hypertension, even in the normotensive offspring of patients with the disease. Low catestatin predicts augmented adrenergic pressor responses, suggesting a mechanism whereby diminished catestatin might increase the risk for later development of hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jackson, R. S., Creemers, J. W. M., Ohagi, S., Raffin-Sanson, M.-L., Sanders, L., Montague, C. T., Hutton, J. C., & O'Rahilly, S. (1997) · Nature Genetics · doi:10.1038/ng0797-303 · Cited by 1,153
Obesity-Induced Hypertension: New Concepts From the Emerging Biology of Obesity
Mark, A. L., Correia, M., Morgan, D. A., Shaffer, R. A., & Haynes, W. G. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.537 · Cited by 185
Obesity–a genetic disease of adipose tissue?
Arner, P. (2000) · British Journal Of Nutrition · doi:10.1017/s0007114500000891 · Cited by 84
Cited by
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Self-citationThe Extended Granin Family: Structure, Function, and Biomedical Implications
Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., & Salton, S. R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0027 · Cited by 348
Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog
Mahapatra, N. R., O’Connor, D. T., Vaingankar, S. M., Hikim, A. P. S., Mahata, M., Ray, S., Staite, E., Wu, H., Gu, Y., Dalton, N., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24354 · Cited by 309
Self-citationZhang, L., Rao, F., Zhang, K., Khandrika, S., Das, M., Vaingankar, S. M., Bao, X., Rana, B. K., Smith, D. W., Wessel, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31093 · Cited by 90
Self-citationAung, G., Niyonsaba, F., Ushio, H., Kajiwara, N., Saito, H., Ikeda, S., Ogawa, H., & Okumura, K. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03395.x · Cited by 89
Metadata
- Authors
- O'Connor, D. T., Kailasam, M. T., Kennedy, B. P., Ziegler, M. G., Yanaihara, N., & Parmer, R. J.
- Venue
- Journal of Hypertension
- Published
- 2002-07
- Volume
- 20
- Issue
- 7
- Pages
- 1335-1345
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2024641334
- Cited by
- 195
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. https://app.cochat.ai/papers/10.1097/00004872-200207000-00020
- The paper
- O'Connor, D. T., Kailasam, M. T., Kennedy, B. P., Ziegler, M. G., Yanaihara, N., & Parmer, R. J. (2002). Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. Journal of Hypertension. https://doi.org/10.1097/00004872-200207000-00020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.